← Back to Screener
Azitra Inc (AZTR)
Price$0.21
Favorite Metrics
Price vs S&P 500 (26W)-77.60%
Price vs S&P 500 (4W)-33.50%
Market Capitalization$3.48M
All Metrics
Book Value / Share (Quarterly)$0.35
P/TBV (Annual)0.82x
Revenue Growth (3Y)-59.15%
Cash Flow / Share (Quarterly)$-1.05
Price vs S&P 500 (YTD)-22.98%
Net Profit Margin (TTM)-1721.97%
EPS (TTM)$-2.06
10-Day Avg Trading Volume0.67M
EPS Excl Extra (TTM)$-2.06
EPS (Annual)$-2.25
ROI (Annual)-273.18%
Net Profit Margin (5Y Avg)-26947.34%
Cash / Share (Quarterly)$0.19
ROA (Last FY)-218.00%
EBITD / Share (TTM)$-1.34
ROE (5Y Avg)-197.36%
Operating Margin (TTM)-1772.18%
Cash Flow / Share (Annual)$-1.05
P/B Ratio0.92x
P/B Ratio (Quarterly)0.75x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)3.97x
Net Interest Coverage (TTM)-66.81x
ROA (TTM)-178.15%
EPS Incl Extra (Annual)$-2.25
Current Ratio (Annual)2.83x
Quick Ratio (Quarterly)2.07x
3-Month Avg Trading Volume8.79M
52-Week Price Return-89.86%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.32
P/S Ratio (Annual)463.97x
Asset Turnover (Annual)0.00x
52-Week High$2.66
Operating Margin (5Y Avg)-32140.94%
EPS Excl Extra (Annual)$-2.25
CapEx CAGR (5Y)-35.68%
26-Week Price Return-68.86%
Quick Ratio (Annual)2.07x
13-Week Price Return-22.14%
Total Debt / Equity (Annual)0.06x
Current Ratio (Quarterly)2.83x
Enterprise Value$1.621
Asset Turnover (TTM)0.07x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-119446.13%
Cash / Share (Annual)$0.19
3-Month Return Std Dev164.20%
Net Income / Employee (TTM)$-1
ROE (Last FY)-288.21%
Net Interest Coverage (Annual)-66.64x
EPS Basic Excl Extra (Annual)$-2.25
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.06x
EPS Incl Extra (TTM)$-2.06
Receivables Turnover (Annual)0.00x
ROI (TTM)-267.46%
P/S Ratio (TTM)8.52x
Pretax Margin (5Y Avg)-26922.75%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.32
Price vs S&P 500 (52W)-124.96%
Year-to-Date Return-18.84%
5-Day Price Return0.89%
EPS Normalized (Annual)$-2.25
ROA (5Y Avg)-159.41%
Net Profit Margin (Annual)-119566.53%
Month-to-Date Return-8.16%
Cash Flow / Share (TTM)$-1.76
EBITD / Share (Annual)$-2.23
Operating Margin (Annual)-146468.53%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-190.52%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-2.06
P/TBV (Quarterly)0.82x
P/B Ratio (Annual)0.75x
Pretax Margin (TTM)-1717.73%
Book Value / Share (Annual)$0.35
Price vs S&P 500 (13W)-25.00%
Beta-1.72x
Revenue / Share (TTM)$0.00
ROE (TTM)-284.75%
52-Week Low$0.10
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
AZTRAzitra Inc | 8.52x | — | — | — | $0.21 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Azitra Inc is a clinical-stage biopharmaceutical company developing engineered microbial and protein therapeutics for rare dermatological diseases. Its proprietary platform identifies and genetically engineers naturally occurring bacteria to create live biotherapeutics, recombinant proteins, and small molecules for precision skin disease treatment. The company's pipeline includes ATR-12 for Netherton syndrome, ATR-04 for papulopustular rash, and ATR-01 for ichthyosis vulgaris.